Skip to main navigation Skip to search Skip to main content

Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing

  • The Somatic Mutation Working Group of Sequencing Quality Control Phase II Consortium
  • Roche Sequencing Solutions Inc.
  • National Institutes of Health
  • Leidos Inc
  • Loma Linda University Health
  • The First Affiliated Hospital of Guangzhou Medical University
  • American Type Culture Collection
  • AbbVie
  • Fudan University
  • Illumina, Inc.
  • Novartis
  • Genentech, Inc
  • Palacký University Olomouc
  • EATRIS ERIC
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • Perron Institute for Neurological and Translational Science
  • University of Tartu
  • University of Helsinki
  • Uppsala University
  • Virginia Polytechnic Institute and State University
  • Sentieon Inc.
  • Immuneering Corporation
  • United States Food and Drug Administration
  • 10x Genomics
  • Translational Genomics Research Institute
  • Cornell University
  • Pacific Biosciences
  • University of Toledo
  • University of Hawai'i at Mānoa
  • Digicon Corporation
  • Environmental Laboratory
  • SAS Institute, Inc.
  • Bristol-Myers Squibb
  • United States Environmental Protection Agency
  • Q2 Solutions
  • Kinghorn Cancer Centre
  • Office of the Commissioner
  • National Institute of Metrology China
  • AstraZeneca Pharmaceuticals LP
  • University of Southern Mississippi

Research output: Contribution to journal › Article › peer-review

Abstract

The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics. Here, we describe reference call sets obtained from paired tumor–normal genomic DNA (gDNA) samples derived from a breast cancer cell line—which is highly heterogeneous, with an aneuploid genome, and enriched in somatic alterations—and a matched lymphoblastoid cell line. We partially validated both somatic mutations and germline variants in these call sets via whole-exome sequencing (WES) with different sequencing platforms and targeted sequencing with >2,000-fold coverage, spanning 82% of genomic regions with high confidence. Although the gDNA reference samples are not representative of primary cancer cells from a clinical sample, when setting up a sequencing pipeline, they not only minimize potential biases from technologies, assays and informatics but also provide a unique resource for benchmarking ‘tumor-only’ or ‘matched tumor–normal’ analyses.

Original languageEnglish
Pages (from-to)1151-1160
Number of pages10
JournalNature Biotechnology
Volume39
Issue number9
DOIs
StatePublished - Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing'. Together they form a unique fingerprint.

Cite this